Blueprint Medicines (NASDAQ:BPMC – Get Rating) issued its quarterly earnings results on Thursday. The biotechnology company reported ($2.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.51, Briefing.com reports. The firm had revenue of $63.29 million during the quarter, compared to analyst estimates of $41.85 million. Blueprint Medicines had […]
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) were up 9.7% on Thursday . The company traded as high as $57.79 and last traded at $56.93. Approximately 369,365 shares changed hands during trading, a decline of 33% from the average daily volume of 548,409 shares. The stock had previously closed at $51.88. Wall Street […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) is scheduled to announce its earnings results before the market opens on Thursday, May 4th. Analysts expect the company to announce earnings of ($2.61) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link. Blueprint Medicines (NASDAQ:BPMC […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) – Equities researchers at Wedbush lowered their Q1 2023 earnings per share estimates for Blueprint Medicines in a research report issued on Monday, April 24th. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will earn ($2.43) per share for the quarter, down from their previous forecast […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totalling 4,240,000 shares, a decrease of 19.4% from the March 15th total of 5,260,000 shares. Based on an average trading volume of 570,700 shares, the days-to-cover ratio is […]